| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.28 | 0.05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.31 | 0.05 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.32 | 0.05 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.06 |